The Hsp90-associated enzyme-FK506 binding protein 51 (FKBP51)-was recently found to co-localize with tau in neurons and physically interact with the microtubule (MT)-associated protein tau in brain tissue from humans who died from Alzheimer's disease (AD). More recently, protein levels of FKBP51 were shown to increase in forebrain neurons with age, further supporting a novel role for FKBP51 in tau processing. The goal of this study is to determine how FKBP51 regulates the biology of tau and whether it is a rational therapeutic target for treating AD, Parkinson's disease (PD), and other tauopathies. Tau aggregation is a central component of Alzheimer's disease (AD) and ~15 other neurodegenerative diseases termed tauopathies. It is now clear that the individual components of the chaperone system exist in an intricate signaling network that can exert pleiotropic effects on tau, facilitating either its degradation or stabilization. Therefore, we endeavored to identify new ways to specifically regulate individual components of the chaperone family that may be targets for therapeutic development. The Hsp90 cochaperone, FKBP51, which possesses both an Hsp90 interacting tetratricopeptide (TPR) domain and a cis-trans peptidyl-prolyl cis-trans isomerase (PPIase) domain, was found to prevent tau clearance and regulate its phosphorylation status. Regulation of the latter is dependent on the PPIase activity of FKBP51. Hsp90 enhances the association of tau with FKBP51, and clearance of tau facilitated by FKBP51 knockdown is dependent on Hsp90 variants. In vitro, FKBP51 stabilizes microtubules with tau in a reaction dependent on FKBP51 PPIase activity. Based on these new findings we propose the following aims to determine the role of FKBP51 in tau biology and pathogenesis. We will 1) investigate how FKBP51 regulates the structural ensembles and aggregation kinetics of tau, 2) determine whether FKBP51 utilizes discreet Hsp90 variants to regulate distinct tau species, and 3) determine whether genetic manipulation of FKBP51 in the brain alters tau-based pathologies and phenotypes in a transgenic mouse model of tauopathy.

Public Health Relevance

The tau protein accumulates in more than 15 neurodegenerative diseases collectively termed "tauopathies", the most common being Alzheimer's disease. Despite this fact, only one drug is currently in clinical trials that targets the tau protein. This is largely due to our lack of understanding of how the brain deals with tau under normal circumstances. Here, we have identified a novel protein that interacts with tau and may represent a novel therapeutic target to treat Alzheimer's disease. This protein, FKBP51, can promote tau removal through a very interesting mechanism, and we will explore whether manipulation of this protein can clear tau protein from the brain. These studies may lead to drug development that can provide sufferers of tauopathies a way to combat their condition, with the ultimate goal being a cure.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
Cellular and Molecular Biology of Neurodegeneration Study Section (CMND)
Program Officer
Corriveau, Roderick A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of South Florida
Schools of Medicine
United States
Zip Code
Karagöz, G Elif; Duarte, Afonso M S; Akoury, Elias et al. (2014) Hsp90-Tau complex reveals molecular basis for specificity in chaperone action. Cell 156:963-74
Orwig, Susan D; Chi, Pamela V; Du, Yuhong et al. (2014) Ligands for glaucoma-associated myocilin discovered by a generic binding assay. ACS Chem Biol 9:517-25
Stothert, Andrew R; Suntharalingam, Amirthaa; Huard, Dustin J E et al. (2014) Exploiting the interaction between Grp94 and aggregated myocilin to treat glaucoma. Hum Mol Genet 23:6470-80
Sabbagh, Jonathan J; O'Leary 3rd, John C; Blair, Laura J et al. (2014) Age-associated epigenetic upregulation of the FKBP5 gene selectively impairs stress resiliency. PLoS One 9:e107241
Selenica, Maj-Linda B; Davtyan, Hayk; Housley, Steven B et al. (2014) Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis. J Neuroinflammation 11:152
Blair, Laura J; Sabbagh, Jonathan J; Dickey, Chad A (2014) Targeting Hsp90 and its co-chaperones to treat Alzheimer's disease. Expert Opin Ther Targets 18:1219-32
Jinwal, Umesh K; Koren 3rd, John; Dickey, Chad A (2013) Reconstructing the Hsp90/Tau Machine. Curr Enzym Inhib 9:41-45
Blair, Laura J; Nordhues, Bryce A; Hill, Shannon E et al. (2013) Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J Clin Invest 123:4158-69
Chiosis, Gabriela; Dickey, Chad A; Johnson, Jill L (2013) A global view of Hsp90 functions. Nat Struct Mol Biol 20:1-4
Abisambra, Jose F; Jinwal, Umesh K; Blair, Laura J et al. (2013) Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation. J Neurosci 33:9498-507

Showing the most recent 10 out of 21 publications